Brii Biosciences Issues 47,409 New Shares in April; Public Float Remains Above 25% Threshold

Bulletin Express05-06

For the month ended 30 April 2026, Brii Biosciences Limited reported a net increase of 47,409 ordinary shares, lifting its outstanding share count (excluding treasury stock) to 721.81 million. Treasury shares were unchanged at 12.72 million, keeping total issued shares at 734.53 million.

The additional shares stemmed entirely from the company’s share-based incentive programmes: • Post-IPO Share Award Scheme: 38,145 shares issued. • 2023 Share Award Scheme: 9,264 shares issued.

No new shares were created through option exercises, warrants or convertibles during the month. As a result, total funds raised from option exercises were HKD 0.

Option pool movements were limited to lapses: • Pre-IPO Share Incentive Scheme options outstanding fell by 0.30 million to 5.55 million. • Post-IPO Share Option Scheme options outstanding declined by 0.52 million to 9.92 million. • 2023 Share Option Scheme options outstanding dropped by 0.26 million to 24.97 million.

Authorised share capital remained unchanged at 1.20 billion ordinary shares with a nominal value of USD 0.000005 each, equivalent to USD 6,000.

Brii Biosciences confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement as of 30 April 2026, and all share issuances complied with applicable listing rules and legal obligations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131437664?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131437664","market":"hk","top_or_hot":-1,"title":"Brii Biosciences Issues 47,409 New Shares in April; Public Float Remains Above 25% Threshold","media":"Bulletin Express","content":"<p>For the month ended 30 April 2026, Brii Biosciences Limited reported a net increase of 47,409 ordinary shares, lifting its outstanding share count (excluding treasury stock) to 721.81 million. Treasury shares were unchanged at 12.72 million, keeping total issued shares at 734.53 million.</p>\n<p>The additional shares stemmed entirely from the company’s share-based incentive programmes:  \n• Post-IPO Share Award Scheme: 38,145 shares issued.  \n• 2023 Share Award Scheme: 9,264 shares issued.</p>\n<p>No new shares were created through option exercises, warrants or convertibles during the month. As a result, total funds raised from option exercises were HKD 0.</p>\n<p>Option pool movements were limited to lapses:  \n• Pre-IPO Share Incentive Scheme options outstanding fell by 0.30 million to 5.55 million.  \n• Post-IPO Share Option Scheme options outstanding declined by 0.52 million to 9.92 million.  \n• 2023 Share Option Scheme options outstanding dropped by 0.26 million to 24.97 million.</p>\n<p>Authorised share capital remained unchanged at 1.20 billion ordinary shares with a nominal value of USD 0.000005 each, equivalent to USD 6,000.</p>\n<p>Brii Biosciences confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement as of 30 April 2026, and all share issuances complied with applicable listing rules and legal obligations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brii Biosciences Issues 47,409 New Shares in April; Public Float Remains Above 25% Threshold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrii Biosciences Issues 47,409 New Shares in April; Public Float Remains Above 25% Threshold\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>For the month ended 30 April 2026, Brii Biosciences Limited reported a net increase of 47,409 ordinary shares, lifting its outstanding share count (excluding treasury stock) to 721.81 million. Treasury shares were unchanged at 12.72 million, keeping total issued shares at 734.53 million.</p>\n<p>The additional shares stemmed entirely from the company’s share-based incentive programmes:  \n• Post-IPO Share Award Scheme: 38,145 shares issued.  \n• 2023 Share Award Scheme: 9,264 shares issued.</p>\n<p>No new shares were created through option exercises, warrants or convertibles during the month. As a result, total funds raised from option exercises were HKD 0.</p>\n<p>Option pool movements were limited to lapses:  \n• Pre-IPO Share Incentive Scheme options outstanding fell by 0.30 million to 5.55 million.  \n• Post-IPO Share Option Scheme options outstanding declined by 0.52 million to 9.92 million.  \n• 2023 Share Option Scheme options outstanding dropped by 0.26 million to 24.97 million.</p>\n<p>Authorised share capital remained unchanged at 1.20 billion ordinary shares with a nominal value of USD 0.000005 each, equivalent to USD 6,000.</p>\n<p>Brii Biosciences confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement as of 30 April 2026, and all share issuances complied with applicable listing rules and legal obligations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02137","symbol_name":"腾盛博药-B","start_time":0,"source_url":"","article_id":"1131437664","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131437664","pubTimestamp":1778058374,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"For the month ended 30 April 2026, Brii Biosciences Limited reported a net increase of 47,409 ordinary shares, lifting its outstanding share count (excluding treasury stock) to 721.81 million....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02137":"腾盛博药-B"},"translate_title":"Brii Biosciences 4月发行47,409股新股；公众持股量仍高于25%门槛","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1},"content_text":"For the month ended 30 April 2026, Brii Biosciences Limited reported a net increase of 47,409 ordinary shares, lifting its outstanding share count (excluding treasury stock) to 721.81 million. Treasury shares were unchanged at 12.72 million, keeping total issued shares at 734.53 million.\nThe additional shares stemmed entirely from the company’s share-based incentive programmes:  \n• Post-IPO Share Award Scheme: 38,145 shares issued.  \n• 2023 Share Award Scheme: 9,264 shares issued.\nNo new shares were created through option exercises, warrants or convertibles during the month. As a result, total funds raised from option exercises were HKD 0.\nOption pool movements were limited to lapses:  \n• Pre-IPO Share Incentive Scheme options outstanding fell by 0.30 million to 5.55 million.  \n• Post-IPO Share Option Scheme options outstanding declined by 0.52 million to 9.92 million.  \n• 2023 Share Option Scheme options outstanding dropped by 0.26 million to 24.97 million.\nAuthorised share capital remained unchanged at 1.20 billion ordinary shares with a nominal value of USD 0.000005 each, equivalent to USD 6,000.\nBrii Biosciences confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement as of 30 April 2026, and all share issuances complied with applicable listing rules and legal obligations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131437664","isCrawlerRequest":true}